Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.

Oleg Gluz,Ulrike Nitz,Matthias Christgen,Michael Braun,Kerstin Luedtke-Heckenkamp,Maren Darsow,Helmut Forstbauer,Jochem Potenberg,Christoph Uleer,Eva Maria Grischke,Bahriye Aktas,Claudia Schumacher,Christine Eulenburg,Katarzyna Jóźwiak,Ronald E. Kates,Monika Graeser,Rachel Wuerstlein,Hans Kreipe,Sherko Kuemmel,Nadia Harbeck

Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.

2021

504Background: In HR+/HER2- N0-1 early BC, postmenopausal patients (pts) with RS™ > 25 and a substantial proportion of premenopausal pts seem to benefit from addition of adjuvant chemotherapy (CT) ...

Keywords:

Internal medicine
Medicine
Chemotherapy
Oncology
Pathological
adjuvant chemotherapy
Endocrine system
Breast cancer
recurrence score

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations